Infliximab therapy increases the frequency of circulating CD16+ monocytes and modifies macrophage cytokine response to bacterial infection

Clinical and Experimental Immunology

Volumn 177, Issue 3, 2014, Pages 703-711

  Nazareth, N ^a   Magro, F ^b,c,d   Silva, J ^a   Duro, M ^a,e   Gracio, D ^b,d   Coelho, R ^c   Appelberg, R ^a   Macedo, G ^c   Sarmento, A ^a,f  

^a UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^b University of Porto   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e Laboratório de Análises Clínicas Vale do Sousa   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cytokine secretion; Inflammatory bowel diseases; Infliximab therapy; Macrophages; Monocyte subsets

Indexed keywords

AZATHIOPRINE; CD14 ANTIGEN; CD16 ANTIGEN; CORTICOTROPIN; INFLIXIMAB; INTERLEUKIN 10; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIAL INFECTION; CELL SUBPOPULATION; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI INFECTION; FEMALE; FREQUENCY MODULATION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REMISSION;

CYTOKINE SECRETION; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB THERAPY; MACROPHAGES; MONOCYTE SUBSETS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; CROHN DISEASE; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-10; LEUKOCYTE COUNT; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, IGG; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84904751087     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12375     Document Type: Article

References (38)

1. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117:514-521.
2. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3:390-407.
3. Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 2010; 24 (Suppl. 1):3-14.
4. Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13:5238-5244.
5. Osterman MT, Lichtenstein GR. Current and future anti-TNF therapy for inflammatory bowel disease. Curr Treat Options Gastroenterol 2007; 10:195-207.
6. Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A. Infliximab in Crohn's disease: early and long-term treatment. Dig Liver Dis 2008; 40 (Suppl. 2):S271-279.
7. D'Haens G, Baert F, van Assche G etal. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371:660-667.
8. Allen PB, Lindsay H, Tham TCK. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol 2010; 10:1. doi:10.1186/1471-230X-10-1.
9. Eissner G, Kirchner S, Lindner H etal. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 2000; 164:6193-6198.
10. Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 2003; 23:76-85.
11. Scallon B, Cai A, Solowski N etal. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:418-426.
12. Vos ACW, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 2011; 140:221-230.
13. Sheikh SZ, Plevy SE. The role of the macrophage in sentinel responses in intestinal immunity. Curr Opin Gastroenterol 2010; 26:578-582.
14. Hume DA. Macrophages as APC and the dendritic cell myth. J Immunol 2008; 181:5829-5835.
15. Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn's disease. Annu Rev Genomics Hum Genet 2009; 10:89-116.
16. Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 2011; 60:1739-1753.
17. Durães C, Machado JC, Portela F etal. Phenotype-genotype profile in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II). Inflamm Bowel Dis 2012; 19:230-239.
18. Hausmann M, Obermeier F, Schreiter K etal. Cathepsin D is up-regulated in inflammatory bowel disease macrophages. Clin Exp Immunol 2004; 136:157-167.
19. Reinecker HC, Steffen M, Witthoeft T etal. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94:174-181.
20. Yang J, Zhang L, Yu C, Yang X-F, Wang H. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomarker Res 2014; 2:1. doi:10.1186/2050-7771-2-1.
21. Wong KL, Yeap WH, Tai JJY, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. Immunol Res 2012; 53:41-57.
22. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum 2012; 64:671-677.
23. Cros J, Cagnard N, Woollard K etal. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33:375-386.
24. Grip O, Bredberg A, Lindgren S, Henriksson G. Increased subpopulations of CD16(+) and CD56(+) blood monocytes in patients with active Crohn's disease. Inflamm Bowel Dis 2007; 13:566-572.
25. + monocytes in the pathogenesis of inflammatory bowel disease. Clin Exp Immunol 2010; 161:332-341.
26. Campos N, Magro F, Castro AR etal. Macrophages from IBD patients exhibit defective tumour necrosis factor-α secretion but otherwise normal or augmented pro-inflammatory responses to infection. Immunobiology 2011; 216:961-970.
27. Dignass A, Van Assche G, Lindsay JO etal. The second European Evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4:28-62.
28. Abubakar I, Myhill D, Aliyu SH, Hunter PR. Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: a systematic review and meta-analysis. Inflamm Bowel Dis 2008; 14:401-410.
29. Feller M, Huwiler K, Stephan R etal. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7:607-613.
30. Smith AM, Rahman FZ, Hayee BH etal. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009; 206:1883-1897.
31. Vos ACW, Wildenberg ME, Arijs I etal. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis 2012; 18:401-408.
32. Benoit M, Desnues B, Mege J-L. Macrophage polarization in bacterial infections. J Immunol 2008; 181:3733-3739.
33. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11:723-737.
34. Söllner L, Shaqireen DO, Kwajah MM, Wu JT, Schwarz H. Signal transduction mechanisms of CD137 ligand in human monocytes. Cell Signal 2007; 19:1899-1908.
35. Lim S-G, Suk K, Lee W-H. Reverse signaling from LIGHT promotes pro-inflammatory responses in the human monocytic leukemia cell line, THP-1. Cell Immunol 2013; 285:10-17.
36. Bode JG, Ehlting C, Häussinger D. The macrophage response towards LPS and its control through the p38MAPK-STAT3 axis. Cell Signal 2012; 24:1185-1194.
37. Deng W, Xie J. NOD2 signaling and role in pathogenic mycobacterium recognition, infection and immunity. Cell Physiol Biochem 2012; 30:953-963.
38. Lutay N, Håkansson G, Alaridah N, Hallgren O, Westergren-Thorsson G, Godaly G. Mycobacteria bypass mucosal NF-kB signalling to induce an epithelial anti-inflammatory IL-22 and IL-10 response. PLOS ONE 2014; 9:e86466.